ReviewJournal of neuroendovascular therapy2025
Embolic Materials in Middle Meningeal Artery Embolization for Chronic Subdural Hematoma.
Review in Journal of neuroendovascular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence of chronic subdural hematoma (cSDH) has been suggested to involve angiogenesis and leakage from the fragile neovasculature within the outer membrane of the hematoma, which is primarily supplied by the distal branches of the middle meningeal artery. Middle meningeal artery embolization (MMAE) has recently gained recognition as an effective treatment, either as a standalone procedure or as an adjunct to burr-hole drainage, to reduce recurrence and reoperation rates. Various embolic materials are used in MMAE, including ethylene-vinyl alcohol copolymer (EVOH)-based agents (Onyx [Medtronic, Irvine, CA, USA], Squid [Balt, Montmorency, France]), polylactide-co-glycolide (PLGA) and polyhydroxyethyl methacrylate (HEMA)-based agent (PHIL; Terumo Neuro, Aliso Viejo, CA, USA), n-butyl cyanoacrylate (NBCA), particulates such as polyvinyl alcohol (PVA) and trisacryl gelatin microspheres (TGM), and coils. EVOH-based and PLGA-HEMA-based agents provide controlled deep distal penetration and durable occlusion, providing the strongest evidence in recent randomized controlled trials. NBCA enables rapid and cost-effective embolization but requires precise technique to prevent complications such as catheter entrapment. Particulates (PVA and TGM) are inexpensive and widely available, yet carry a higher recanalization risk and are often combined with coils or liquid embolics. Coils alone have limited efficacy, although they serve a protective role during liquid embolic injection. In Japan, NBCA is the predominant material, often combined with coils or particles, due to insurance coverage and guideline recommendations. Comparative evidence among embolic agents remains limited, highlighting the need for further studies to define optimal material selection and standardize MMAE strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.